Epidemiology and Screening for Hepatitis C Infection

Size: px
Start display at page:

Download "Epidemiology and Screening for Hepatitis C Infection"

Transcription

1 Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

2 Epidemiology/Screening for Hepatitis C Natural History of HCV infection Trends in HCV transmission, disease, mortality Health benefits of HCV Testing, care and treatment Testing algorithms/strategies to screen patients for HCV infection (CDC cohort)

3 The Natural History of HCV Infection Acute Hepatitis C Chronic Hepatitis 60% 85% Cirrhosis 10% 20% years Decompensation 3 6%/year HCC 1 4%/year Death 2 4%/year NIH Consensus Development Panel. Gastroenterology. 2002;123: ; Serfaty L, et al. Hepatology. 1998;27: ; Fattovich G, et al. Gastroenterology. 1997;112:

4 Prevalence of Chronic Hepatitis C Infection In the US, million people are living with chronic HCV infection; 75% are unaware they are infected Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Available at: Accessed January 6, Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C; 2010.

5 Prevalence of HCV in Select Populations Incarcerated ~ 330,000 to 860,000 (16 41%) 1 Injection drug users ~ 300,000 Alcoholics (80 90%) 2,3 ~ 240,000 (11 36%) 5 HIV-infected ~ 300,000 (30%) 4 Male 63% Female 37% Homeless ~ 175,000 (22%) 7 Veterans ~ 280,000 (4%) 8 Living below poverty level ~ 940,000 (3.2%) 6 Children (6 18 years old) ~ 100,000 (0.1%) 9 Adapted from: 1. CDC. MMWR. 2003;52(RR-1):1-33; 2. Edlin B. Hepatol. 2002;36(5 suppl 1):S210-S219; 3. NHSDA Report 2003; 4. Poles M, et al. Clin Infect Dis. 2000;31: ; 5. LaBrecque D, et al. Hepatitis C Choices. 2002:7-15; 6. Alter M, et al. N Engl J Med. 1999;341: ; 7. Nyamathi A, et al. J Gen Intern Med. 2002;17: ; 8. Dominitz J, et al. Hepatology. 2005;41:88-96; 9. Jonas M. Hepatol. 2002;36(5 suppl 1):S173-S178.

6 Number of cases Projected Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis Due to HCV 160, , , ,000 80,000 60,000 40,000 20,000 Decompensated cirrhosis Hepatocellular cancer Year Davis GL, et al. Gastroenterology. 2010;138(2):

7 Incidence of chronic HCV by county, Oregon, (cases/100,000) 7

8 Total reported cases of chronic HCV By 2013, 47,435 cases were reported to Oregon s HCV registry Assuming that at least 50% of Oregonians with HCV are unaware of their diagnosis, the actual number is probably closer to 95,000

9 Chronic viral hepatitis cases by year of liver cancer diagnosis, Oregon, HCV (n=763) HBV (n=196) Not Hepatitis In 2012, 8% of liver cancer cases had chronic HBV, while 47% had chronic HCV

10 Age and sex of cases of HCVassociated liver cancer, HCV-associated liver cancer (n=611) Age Group No. (%) 0-29 years 2 (0.4) years 0 (0) years 42 (7) years 321 (53) years 201 (33) 70 and older 45 (7) Sex Male 475 (78) Female 136 (22)

11 HCV-associated hospitalizations Oregon, (n=3,917) Characteristic Finding Age 83% aged years only 8% were > 65 years Sex 2/3 male Payer 30% Medicare 32% Medicaid

12 Percent of Hospitalizations Categories of advanced liver disease in patients with HCV-related hospitalizations, Oregon, , (n=3,917)

13 Mean length of stay and healthcare charges per admission, HCV-related hospitalizations Oregon, (n= 3,917) Condition Mean length of hospital stay in days Mean healthcare charges per admission Cirrhosis (n=2,919) 4.4 $23,942 Decompensated Cirrhosis (n=2,969) 4.9 $27,234 Other chronic liver disease (849) 4.4 $22,230 Liver cancer (N=597) 5.1 $34,281 Liver Transplant (n=103) 6.9 $52,245 Average charges per hospitalization were $26,961 and the total average charges per year were $21,149,111

14 Number of Transplants Annual number of liver transplants performed at OHSU by etiology, Other HCV HBV transplants performed on average annually; 18 (53%) for HCV

15 Age-adjusted Rates per 100,000 Age-adjusted mortality from HCV and HIV in Oregon and from HCV nationally, Age-adjusted mortality rates % of HCVrelated deaths were in persons aged years Only 16% were > 65 years OR HCV US HCV OR HIV 15

16 The Majority of Patients are Asymptomatic Symptoms of HCV may include: Fatigue Nausea Poor appetite/weight loss Muscle and joint pains/weakness Jaundice Abdominal pain or swelling Dark urine Itching Fluid retention Some patients may not have any symptoms for up to 20 years, and yet have liver disease progression CDC. Accessed June 2011.

17 Pts (%) Hepatitis C Virus (HCV) in the US: Gaps in Current Practice % % 43% 40 27% 20 17% 16% 9% 0 Chronic Diagnosed HCV Infected and Aware Access to Outpatient Care HCV RNA Confirmed Underwent Liver Biopsy Prescribed HCV Treatment Achieved Sustained Viral Response n = 3,500,000 1,743,000 1,514, , , , ,859 Yehia BR, et al. PLoS One. 2014;9:e

18 Primary Care Clinicians Have a Critical Role in Hepatitis C Care US prevalence of hepatitis C infection [1] 2% Average pt load for primary care clinician [2] x 2000 pts Average primary care clinician has 40 pts with hepatitis C infection in his/her practice [2] 1. Chak E, et al. Liver Int. 2011;31: Ferrante JM, et al. Fam Med. 2008;40:

19 Prevalence of Hepatitis C Positive (%) Hepatitis C Prevalence is Increased in Baby Boomers Prevalence of Hepatitis C Antibody Positivity in US Population by Sex by Yr of Birth (NHANES III) [1] Screening recommended Male Female Yr of Birth Iwasaki K, et al. ISPOR Abstract PG17.

20 CDC, USPSTF, and AASLD/IDSA HCV Screening Recommendations Population Recommendation Age One-time screening is recommended for persons born between 1945 and 1965, without ascertainment of HCV risk [1-3] Risk One-time screening is recommended for persons with these risk factors [1,3] : History of illicit injection drug use (IDU) or intranasal illicit drug use History of long-term hemodialysis Receiving a tattoo in an unregulated facility/setting Healthcare workers upon accidental exposure Children born to anti-hcv positive mothers History of transfusion with blood or organ transplantation Were ever in prison HIV infection Chronic liver disease/hepatitis with unknown cause, including elevated liver enzymes Annual screening is recommended for current IDUs and HIV-infected MSM [3] 1. Smith BD, et al. MMWR Recomm Rep. 2012;61(RR-4): US Preventive Services Task Force. HCV Screening Guidelines AASLD-IDSA. HCV Guidelines 2016.

21 Recommended Testing Sequence for Identifying Current HCV Infection HCV antibody test Reactive HCV RNA test Detect ed Current HCV infection Provide care or link to care Nonreactive Not detected Stop No current HCV infection Additional testing as appropriate CDC. MMWR Morb Mortal Wkly Rep. 2013;62:

Updates in the Treatment of Hepatitis C

Updates in the Treatment of Hepatitis C Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose

More information

Hepatitis C Update: A Growing Challenge With Evolving Management Solutions

Hepatitis C Update: A Growing Challenge With Evolving Management Solutions Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Digestive & Liver Disease Wellness

Digestive & Liver Disease Wellness Digestive & Liver Disease Wellness Colorectal Cancer Screening & Prevention According to the American Cancer Society, this year 136,830 people in the U.S. According will be to diagnosed the American with

More information

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period Quality ID #387 (NQF 3060): Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL

More information

Strategies to Address HCV

Strategies to Address HCV Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The

More information

i Screening and Natural History

i Screening and Natural History HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

STOP Hepatocellular Carcinoma

STOP Hepatocellular Carcinoma STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern

More information

HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis

HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis Wari Allison MD, PhD Assistant Professor/Research Dept. of Medicine/Infectious Disease Medical Director

More information

Zobair M. Younossi M.D., M.P.H., FACG

Zobair M. Younossi M.D., M.P.H., FACG HCV Epidemiology and Cohort Screening Guidelines Zobair M. Younossi, MD, MPH, FACG Consultant or Advisor: Conatus, Enterome, Gilead, Merck, Salix, Vertex, J & J HCV Epidemiology and Cohort Screening Guidelines

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Numbers HCV and HIV Epidemiology in the US

Numbers HCV and HIV Epidemiology in the US By The Numbers HCV and HIV Epidemiology in the US Coinfection Fridays Session 1 18 January 2019 Christopher B. Hurt, MD Associate Professor of Medicine Co-Director, North Carolina AIDS Training & Education

More information

Recommendations for Hepatitis C Screening

Recommendations for Hepatitis C Screening Hepatitis C Online PDF created June 16, 2018, 9:14 am Recommendations for Hepatitis C Screening This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection

More information

Hepatitis C in the United States : Preparing for the Test and Cure Era

Hepatitis C in the United States : Preparing for the Test and Cure Era Hepatitis C in the United States : Preparing for the Test and Cure Era Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Centers for Disease Control and Prevention

More information

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids

More information

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States

More information

Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD

Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study

More information

HCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations

HCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations HCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations Paul Y. Kwo, MD, FACG Professor of Medicine Director of Hepatology Stanford University Hepatitis C Virus Page 1 of 22 The

More information

Contemporary Management of HIV-HCV Coinfection

Contemporary Management of HIV-HCV Coinfection Contemporary Management of HIV-HCV Coinfection Elizabeth Sherman, PharmD, AAHIVP Faculty, South Florida - Southeast AIDS Education & Training Center HIV/AIDS Clinical Pharmacist, Memorial Healthcare System

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Is Elimination of Hepatitis C Possible?

Is Elimination of Hepatitis C Possible? Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Overview of Hepatitis C Virus: The Challenge & The Opportunity. Cody A. Chastain, MD

Overview of Hepatitis C Virus: The Challenge & The Opportunity. Cody A. Chastain, MD Overview of Hepatitis C Virus: The Challenge & The Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key faculty

More information

Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are

More information

The Dawn of a New Era: Hepatitis C

The Dawn of a New Era: Hepatitis C The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should

More information

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.

More information

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Hep C Update N. Randy Kolb, MD Speakers has received Funding

More information

Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD

Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular

More information

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines

More information

Hepatitis C. Core slides

Hepatitis C. Core slides Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and

More information

Hepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?

Hepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations? Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

Update on HCV and other infections related to injection drug use. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention

Update on HCV and other infections related to injection drug use. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention Update on HCV and other infections related to injection drug use Ann Thomas, MD, MPH Acute and Communicable Disease Prevention Dec 14, 2018 Overview Update on NHANES prevalence data Trends in HCV, HIV

More information

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis

More information

Hepatitis C. David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center

Hepatitis C. David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center Hepatitis C David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center DISCLOSURE The speaker and members of the planning committee do

More information

After the Cure: Looking Ahead in HCV Management. Nancy Reau, MD

After the Cure: Looking Ahead in HCV Management. Nancy Reau, MD After the Cure: Looking Ahead in HCV Management Nancy Reau, MD Objectives 1. Discuss current recommendations in HCV screening, performance and limitations 2. Discuss linkage to care, hurdles and strategies

More information

Geo-epidemiology of Hepatitis C in Northeast Indiana

Geo-epidemiology of Hepatitis C in Northeast Indiana Geo-epidemiology of Hepatitis C in Northeast Indiana Shori Gerardot, Ashley Cross, Atit Patel, Kassidy Beck MS, Scott M. Stienecker MD, and Teresa A. Beam PhD Hepatitis C (HCV) ~180 million worldwide ~2.7-3.9

More information

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965

More information

Public Health Response to HCV in Oregon: Need for Screening and Treatment. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention

Public Health Response to HCV in Oregon: Need for Screening and Treatment. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention Public Health Response to HCV in Oregon: Need for Screening and Treatment Ann Thomas, MD, MPH Acute and Communicable Disease Prevention November 29, 2018 Outline I. Epidemiology of HCV in OR acute HCV,

More information

HCV epi overview. Brigg Reilley, NPAIHB, Nat l Program Epidemiologist,

HCV epi overview. Brigg Reilley, NPAIHB, Nat l Program Epidemiologist, HCV epi overview Brigg Reilley, NPAIHB, Nat l Program Epidemiologist, brigg.reilley@ihs.gov In 20 minutes, we will cover Transmission/trends Screening HCV estimates: national, IHS, OK (federal), Cherokee

More information

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at: ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis

More information

Patient Discussion Guide

Patient Discussion Guide Patient Discussion Guide INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS Please click to see full Prescribing Information for HARVONI, including BOXED WARNING. CHRONIC HEPATITIS C (HEP C) GENOTYPE

More information

Update on HIV-HCV Epidemiology and Natural History

Update on HIV-HCV Epidemiology and Natural History Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,

More information

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural

More information

Hepatitis C in Disclosures

Hepatitis C in Disclosures Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor

More information

Hepatitis C: Let s Talk About It. Causes of Hepatitis

Hepatitis C: Let s Talk About It. Causes of Hepatitis Hepatitis C: Let s Talk About It Susan Thompson, RN, MPH Technical Assistance and Training Program NC Communicable Disease Branch July 2012 Causes of Hepatitis any swelling, inflammation, or irritation

More information

@PremierHA #AdvisorLive. Download today s slides at

@PremierHA #AdvisorLive. Download today s slides at @PremierHA #AdvisorLive Download today s slides at www.premierinc.com/events Logistics Audio Use your computer speakers or dial in with the number on your screen Notes Download today s slides from the

More information

Stop HCC THE CASE FOR HEPATITIS C SCREENING OF BABY BOOMERS TO PREVENT LIVER FAILURE AND CANCER

Stop HCC THE CASE FOR HEPATITIS C SCREENING OF BABY BOOMERS TO PREVENT LIVER FAILURE AND CANCER Stop HCC THE CASE FOR HEPATITIS C SCREENING OF BABY BOOMERS TO PREVENT LIVER FAILURE AND CANCER BARBARA J TURNER, MD, MSED J a m e s D a n d O n a I D y e P r o f e s s o r o f M e d i c i n e D i r e

More information

HEPATITIS C: UPDATE AND MANAGEMENT

HEPATITIS C: UPDATE AND MANAGEMENT HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I

More information

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis

More information

Hepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas

Hepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis

More information

High Yield and Feasibility of Baby Boomer Birth Cohort HCV Screening in Two Urban, Academic Emergency Departments

High Yield and Feasibility of Baby Boomer Birth Cohort HCV Screening in Two Urban, Academic Emergency Departments High Yield and Feasibility of Baby Boomer Birth Cohort HCV Screening in Two Urban, Academic Emergency Departments James W Galbraith, MD 1 ; Jordan Morgan, MPH 1 ; Joel Rodgers, MPH 1 ; Ricardo Franco,

More information

Hepatitis B infection

Hepatitis B infection Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect

More information

HIV Prevention, Hepatitis Programming, and Drug User Health An Integrated Service Model at SFDPH. Protecting and Promoting Health and Equity

HIV Prevention, Hepatitis Programming, and Drug User Health An Integrated Service Model at SFDPH. Protecting and Promoting Health and Equity HIV Prevention, Hepatitis Programming, and Drug User Health An Integrated Service Model at SFDPH Protecting and Promoting Health and Equity CHE&P 3/12/15 Presented by: Katie Burk, MPH 1 San Francisco Department

More information

Viral Hepatitis Update: Screening, Vaccination, and Treatment

Viral Hepatitis Update: Screening, Vaccination, and Treatment Viral Hepatitis Update: Screening, Vaccination, and Treatment Alaska Maternal Child Health & Immunization Conference September 28, 2016 Prabhu Gounder, MD, MPH, FACP Medical officer, CDC Arctic Investigations

More information

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious

More information

Hepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches

Hepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/

More information

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Open Access Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus

Open Access Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus Send Orders for Reprints to reprints@benthamscience.net The Open Public Health Journal, 2014, 7, 1-5 1 Open Access Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus Koji

More information

Hepatitis C in Dr. Michael Bays D.O.

Hepatitis C in Dr. Michael Bays D.O. Hepatitis C in 2015 Dr. Michael Bays D.O. HCV Virology Member of the Flavivirus family (Yellow Fever, Dengue) Hepacivirus genus Enveloped, positive, singlestranded RNA virus 9.6 Kb genome encodes a single

More information

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Background and affiliations BS (MIT); 3 years in international health (Mexico City and Honduras with Peace Corps); MS (Colorado State University);

More information

What is Hepatitis C Virus (HCV)?

What is Hepatitis C Virus (HCV)? HEPATITIS C VIRUS (HCV) What is Hepatitis C Virus (HCV)? Hepatitis is an inflammation (swelling or tenderness) of the liver. Hepatitis C virus (HCV) is the most common form of viral hepatitis and usually

More information

US Proposal to Transform Response to Hepatitis B and C. Anna S. F. Lok, MD University of Michigan Ann Arbor, MI, USA

US Proposal to Transform Response to Hepatitis B and C. Anna S. F. Lok, MD University of Michigan Ann Arbor, MI, USA US Proposal to Transform Response to Hepatitis B and C Anna S. F. Lok, MD University of Michigan Ann Arbor, MI, USA US Proposal to Transform Response to Hepatitis B and C Burden of disease Deficiencies

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Hepatitis Case Investigation

Hepatitis Case Investigation * indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology

More information

HEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017

HEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017 HEPATITIS C Whitney Dickson, PharmD, BCPS October 12 th, 2017 MY BACKGROUND Pharmacy School: University of California San Diego Pharmacy Practice Residency (PGY1): University of Illinois at Chicago HIV/Hep

More information

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. What is Hepatitis? Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. Hepatitis A and E are not chronic and are mostly present in areas

More information

Hepatitis situation in the Republic of Macedonia

Hepatitis situation in the Republic of Macedonia Hepatitis situation in the Republic of Macedonia Presented by Viktorija Chaloska Ivanova University Clinic of Gastroenterology Skopje, Republic of Macedonia Hepatitis Prevalence/incidence in Macedonia

More information

Hepatitis C Screening For Baby Boomers in Primary Care. Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018

Hepatitis C Screening For Baby Boomers in Primary Care. Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018 Hepatitis C Screening For Baby Boomers in Primary Care Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018 Disclosures No disclosures Objectives Recognize the importance of diagnosing Hepatitis C (HCV)

More information

Integrating Hepatitis C into Drug Treatment Settings

Integrating Hepatitis C into Drug Treatment Settings Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis

More information

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

Management of Chronic HCV 2017 and Beyond

Management of Chronic HCV 2017 and Beyond Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence

More information

Challenges for viral hepatitis prevention in Latin American

Challenges for viral hepatitis prevention in Latin American Challenges for viral hepatitis prevention in Latin American One in three people on earth has been exposed to hepatitis B or C viruses (HBV and HCV); HBV and HCV are responsible for 57% of cirrhosis and

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hepatitis_c 1/1/2019 N/A 1/1/2020 1/1/2019 Description of Procedure or Service Description Hepatitis C is

More information

Hepatitis C in the HIV Co-infected Population: Where are we today?

Hepatitis C in the HIV Co-infected Population: Where are we today? Hepatitis C in the HIV Co-infected Population: Where are we today? Sherilyn Brinkley MSN, CRNP Viral Hepatitis Center John G. Bartlett Specialty Practice 1 Disclosures Consulting and fees for non-cme/ce

More information

4/8/16. Learning Objectives. Overview Hepatitis C. What IS Hepatitis C?? Overview Hepatitis C

4/8/16. Learning Objectives. Overview Hepatitis C. What IS Hepatitis C?? Overview Hepatitis C Hepatitis C what Primary Care Providers Need To Know: A 2016 Update Maria Steele, ARNP FNP-C Iowa Digestive Disease Center Clive, Iowa 515-288-6097 Learning Objectives To understand the trends in Hepatitis

More information

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018 Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial

More information

Hepatitis C What is it? Should I get tested?

Hepatitis C What is it? Should I get tested? Hepatitis C What is it? Should I get tested? Everything you need to know about hepatitis C Mazzoni Center Hepatitis A, B, and C are different diseases, and the viruses are spread in different ways. liver

More information

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES David Njabulo Whiters, PhD, MSW, NCAC II Consultant, Great Lakes Addiction Technology Transfer Center Setting

More information

Chronic Hepatitis C in African Americans: Challenges and Opportunities

Chronic Hepatitis C in African Americans: Challenges and Opportunities Chronic Hepatitis C in African Americans: Challenges and Opportunities Charles D. Howell, MD Professor and Chairman Department of Medicine Howard University Washington, DC Speaker Disclosure The speaker

More information

Program Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.

Program Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity. Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through

More information

UPDATE ON HEPATITIS C

UPDATE ON HEPATITIS C UPDATE ON HEPATITIS C May 5, 2017 Dan Virnig, MD Park Nicollet / HealthPartners Thanks to everyone who shared slides and information Adnan Said, MD, MS Terry Box, MD with CCO Christine Strahl,, HP Clinical

More information

National Viral Hepatitis Action Plan Priority Populations Approach

National Viral Hepatitis Action Plan Priority Populations Approach National Viral Hepatitis Action Plan Priority Populations Approach November 29, 2017 Corinna Dan, RN, MPH Office of HIV/AIDS and Infectious Disease Policy Office of the Assistant Secretary for Health Department

More information

HEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT

HEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT HEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT 6/27/2014 C Stands for Cure. Kirti Shetty, MD Associate Professor Of Medicine Director Of Hepatology National Capital Region 1 DISCLOSURES Grant

More information

Viral Hepatitis - Historical Perspective

Viral Hepatitis - Historical Perspective Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and

More information

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or

More information

Hepatitis C risk factors in a Cambodian American population in Lowell, Massachusetts

Hepatitis C risk factors in a Cambodian American population in Lowell, Massachusetts Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2015 Hepatitis C risk factors in a Cambodian American population in Lowell, Massachusetts Yu,

More information

Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)

Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead: CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled

More information

Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018

Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018 Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018 2 Project SUCCEED Team Natalie Octave, MPH, CHES Project

More information

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection

More information

Towards the Goal of HCV Elimination: UCSF Project ECHO

Towards the Goal of HCV Elimination: UCSF Project ECHO Towards the Goal of HCV Elimination: UCSF Project ECHO Norah Terrault, MD Professor of Medicine and Surgery University of California San Francisco Direct acting antiviral drugs (DAAs) have been transformative

More information

HEPATITIS C TREATMENT UPDATE

HEPATITIS C TREATMENT UPDATE HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%

More information

Learning Objectives. Upon completion, participants should be able to:

Learning Objectives. Upon completion, participants should be able to: Learning Objectives Upon completion, participants should be able to: Understand the magnitude of the HCV problem and the natural history and consequences of HCV infection Implement guideline-recommended

More information